1. Scrip
  3. >>Clinical Trials

Merrimack Pharma Cutting Jobs Again After Shelving Third Cancer Drug In Year

 
• By Sten Stovall

Merrimack Pharmaceuticals is ending development of its lead drug MM-310 because of safety concerns, triggering a fresh round of job cuts at the troubled Cambridge, Massachusetts-based biotech.

Crisis
MM-310's Failure Deepens Crisis At Merrimack Pharma • Source: Shutterstock

Crisis-torn Merrimack Pharmaceuticals Inc. plans another round of layoffs after shelving its third cancer drug in the last year, and will now place its corporate hopes on two preclinical assets.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

 
• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

More from R&D